These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 30874360)

  • 1. DLL3 regulates the migration and invasion of small cell lung cancer by modulating Snail.
    Furuta M; Kikuchi H; Shoji T; Takashima Y; Kikuchi E; Kikuchi J; Kinoshita I; Dosaka-Akita H; Sakakibara-Konishi J
    Cancer Sci; 2019 May; 110(5):1599-1608. PubMed ID: 30874360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DLL3 is regulated by LIN28B and miR-518d-5p and regulates cell proliferation, migration and chemotherapy response in advanced small cell lung cancer.
    Huang J; Cao D; Sha J; Zhu X; Han S
    Biochem Biophys Res Commun; 2019 Jun; 514(3):853-860. PubMed ID: 31079917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of DLL3 and ASCL1 in Surgically Resected Small Cell Lung Cancer (HOT1702).
    Furuta M; Sakakibara-Konishi J; Kikuchi H; Yokouchi H; Nishihara H; Minemura H; Harada M; Yamazaki S; Akie K; Fujita Y; Takamura K; Kojima T; Harada T; Minami Y; Watanabe N; Oizumi S; Suzuki H; Nishimura M; Dosaka-Akita H; Isobe H;
    Oncologist; 2019 Nov; 24(11):e1172-e1179. PubMed ID: 31068386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of delta-like protein 3 is reproducibly present in a subset of small cell lung carcinomas and pulmonary carcinoid tumors.
    Xie H; Boland JM; Maleszewski JJ; Aubry MC; Yi ES; Jenkins SM; Koepplin JW; Terra SBSP; Mansfield AS; Roden AC
    Lung Cancer; 2019 Sep; 135():73-79. PubMed ID: 31447005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Noninvasive Interrogation of DLL3 Expression in Metastatic Small Cell Lung Cancer.
    Sharma SK; Pourat J; Abdel-Atti D; Carlin SD; Piersigilli A; Bankovich AJ; Gardner EE; Hamdy O; Isse K; Bheddah S; Sandoval J; Cunanan KM; Johansen EB; Allaj V; Sisodiya V; Liu D; Zeglis BM; Rudin CM; Dylla SJ; Poirier JT; Lewis JS
    Cancer Res; 2017 Jul; 77(14):3931-3941. PubMed ID: 28487384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Knockdown of Delta-like 3 restricts lipopolysaccharide-induced inflammation, migration and invasion of A2058 melanoma cells via blocking Twist1-mediated epithelial-mesenchymal transition.
    Ding X; Li F; Zhang L
    Life Sci; 2019 Jun; 226():149-155. PubMed ID: 30981764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Near infrared photoimmunotherapy targeting DLL3 for small cell lung cancer.
    Isobe Y; Sato K; Nishinaga Y; Takahashi K; Taki S; Yasui H; Shimizu M; Endo R; Koike C; Kuramoto N; Yukawa H; Nakamura S; Fukui T; Kawaguchi K; Chen-Yoshikawa TF; Baba Y; Hasegawa Y
    EBioMedicine; 2020 Feb; 52():102632. PubMed ID: 31981983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Notch pathway in small-cell lung cancer: from preclinical evidence to therapeutic challenges.
    Leonetti A; Facchinetti F; Minari R; Cortellini A; Rolfo CD; Giovannetti E; Tiseo M
    Cell Oncol (Dordr); 2019 Jun; 42(3):261-273. PubMed ID: 30968324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of DLL3-positive circulating tumor cells (CTCs) in patients with small cell lung cancer (SCLC) and evaluation of their clinical relevance during front-line treatment.
    Messaritakis I; Nikolaou M; Koinis F; Politaki E; Koutsopoulos A; Lagoudaki E; Vetsika EK; Georgoulias V; Kotsakis A
    Lung Cancer; 2019 Sep; 135():33-39. PubMed ID: 31447000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ascl1-induced Wnt11 regulates neuroendocrine differentiation, cell proliferation, and E-cadherin expression in small-cell lung cancer and Wnt11 regulates small-cell lung cancer biology.
    Tenjin Y; Kudoh S; Kubota S; Yamada T; Matsuo A; Sato Y; Ichimura T; Kohrogi H; Sashida G; Sakagami T; Ito T
    Lab Invest; 2019 Nov; 99(11):1622-1635. PubMed ID: 31231131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Notch ligand delta-like 3 promotes tumor growth and inhibits Notch signaling in lung cancer cells in mice.
    Deng SM; Yan XC; Liang L; Wang L; Liu Y; Duan JL; Yang ZY; Chang TF; Ruan B; Zheng QJ; Han H
    Biochem Biophys Res Commun; 2017 Jan; 483(1):488-494. PubMed ID: 28007595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ASCL1 and DLL3 expressions and their clinicopathological implications in surgically resected pure small cell lung cancer: A study of 247 cases from the National Cancer Center of China.
    Hu C; Dong J; Liu L; Liu J; Sun X; Teng F; Wang X; Ying J; Li J; Xing P; Yang L
    Thorac Cancer; 2022 Feb; 13(3):338-345. PubMed ID: 34931456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics of Notch signaling pathway and its correlation with immune microenvironment in SCLC.
    Li W; Ye L; Huang Y; Zhou F; Wu C; Wu F; He Y; Li X; Wang H; Xiong A; Gao G; Wang L; Su C; Ren S; Chen X; Zhou C
    Lung Cancer; 2022 May; 167():25-33. PubMed ID: 35381444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of Delta-like protein 3 expression in patients with small cell lung cancer.
    Tanaka K; Isse K; Fujihira T; Takenoyama M; Saunders L; Bheddah S; Nakanishi Y; Okamoto I
    Lung Cancer; 2018 Jan; 115():116-120. PubMed ID: 29290251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of four DLL3 antibodies performance in high grade neuroendocrine lung tumor samples and cell cultures.
    Brcic L; Kuchler C; Eidenhammer S; Pabst D; Quehenberger F; Gazdar AF; Popper H
    Diagn Pathol; 2019 May; 14(1):47. PubMed ID: 31109352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Bispecific DLL3/CD3 IgG-Like T-Cell Engaging Antibody Induces Antitumor Responses in Small Cell Lung Cancer.
    Hipp S; Voynov V; Drobits-Handl B; Giragossian C; Trapani F; Nixon AE; Scheer JM; Adam PJ
    Clin Cancer Res; 2020 Oct; 26(19):5258-5268. PubMed ID: 32554516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study.
    Morgensztern D; Besse B; Greillier L; Santana-Davila R; Ready N; Hann CL; Glisson BS; Farago AF; Dowlati A; Rudin CM; Le Moulec S; Lally S; Yalamanchili S; Wolf J; Govindan R; Carbone DP
    Clin Cancer Res; 2019 Dec; 25(23):6958-6966. PubMed ID: 31506387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel metastatic promoter CEMIP and its downstream molecular targets and signaling pathway of cellular migration and invasion in SCLC cells based on proteome analysis.
    Li L; Pan Y; Mo X; Wei T; Song J; Luo M; Huang G; Teng C; Liang K; Mao N; Yang J
    J Cancer Res Clin Oncol; 2020 Oct; 146(10):2519-2534. PubMed ID: 32648226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DB-1314, a novel DLL3-targeting ADC with DNA topoisomerase I inhibitor, exhibits promising safety profile and therapeutic efficacy in preclinical small cell lung cancer models.
    Lin S; Zhang Y; Yao J; Yang J; Qiu Y; Zhu Z; Hua H
    J Transl Med; 2024 Aug; 22(1):766. PubMed ID: 39143619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNA-485-5p suppresses the proliferation, migration and invasion of small cell lung cancer cells by targeting flotillin-2.
    Gao F; Wu H; Wang R; Guo Y; Zhang Z; Wang T; Zhang G; Liu C; Liu J
    Bioengineered; 2019 Dec; 10(1):1-12. PubMed ID: 30836864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.